

FORM PTO-1390 MODIFIED	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	<div style="font-size: 1.2em; font-weight: bold;">IAP13 Rec'd PCT/PTO 27 NOV 2006</div> RECEIVING OFFICE NUMBER 1090-127
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <div style="text-align: center; font-weight: bold;">10/590,450</div>
INTERNATIONAL APPLICATION NO. PCT/GB2005/000780	INTERNATIONAL FILING DATE 02 March 2005	PRIORITY DATE CLAIMED 03 March 2004
TITLE OF INVENTION <div style="text-align: center; font-weight: bold;">USE OF NEW LIPOXYGENASE INHIBITORS</div>		
APPLICANT(S) FOR DO/EO/US <div style="text-align: center; font-weight: bold;">OLOFSSON et al</div>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The U.S. has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (pages specification, claims & abstract (claims), sheets drawings). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (pages specification, claims & abstract (claims), sheets drawings, page Certificate of Translation). b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> a. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <ol style="list-style-type: none"> b. <input type="checkbox"/> Declaration was submitted to the International Bureau during International Phase (see copies of Declaration (page Form PCT/RO/101 and Form PCT/IB/371 and first page of printed publication acknowledging receipt thereof attached). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 To 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <ol style="list-style-type: none"> a. <input type="checkbox"/> A FIRST preliminary amendment. b. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 C.F.R. § 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information. Exclusive Substitute Power of Attorney; Identification of Practitioners to be Recognized 		

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/590,450		INTERNATIONAL APPLICATION NO. PCT/GB2005/000780		ATTORNEY'S DOCKET NUMBER 1090-127	
<input checked="" type="checkbox"/> The following fees are submitted:					
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):					
21. <input type="checkbox"/>	Basic national fee			\$300.00 (1631)/\$150.00 (2631)	\$ 0.00
22. <input type="checkbox"/>	Examination Fee			\$0 (1643/2643)	\$ 0.00
				\$200.00 (1633)/\$100.00 (2633)	
23. <input type="checkbox"/>	Search Fee			\$0 (1640/2640)	
				\$100 (1641)/\$50 (2641)	
				\$400 (1642)/\$200 (2642)	
				\$500.00 (1632)/\$250.00 (2632)	\$ 0.00
TOTAL OF ABOVE CALCULATIONS					\$ 0.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)		RATE	
114 -100	14 /50 =	0.28		\$250.00 (1681)	\$ 0.00
				\$125.00 (2681)	
Surcharge of \$130.00 (1617)/\$65.00 (2617) for furnishing the oath or declaration later than <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).					
CLAIMS		NUMBER FILED	# EXTRA	RATE	
Total Claims	36	minus 36 =	0 X	\$50.00 (1615)/	\$25.00 (2615)
					\$ 0.00
Independent Claims	2	minus 3 =	0 X	\$200.00 (1614)	\$100.00 (2614)
					\$ 0.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)				\$360.00 (1616)/\$180.00 (2616)	\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s): One Month Extension \$120.00 (1251)/\$60.00 (2251); Two Month Extensions \$450.00 (1252)/\$225.00 (2252); Three Month Extensions \$1020.00 (1253)/\$510.00 (2253); Four Month Extensions \$1590.00 (1254)/\$795.00 (2254)					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
Processing fee of \$130.00 (1618), for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					
TOTAL NATIONAL FEE =					\$ 0.00
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 (8021) per property					
					\$ 40.00
Fee for Petition to Revive Unintentionally Abandoned Application; \$1500.00 (1453) / \$750.00 (2453)					
TOTAL FEES ENCLOSED =					\$ 40.00
					Amount to be refunded: \$
					Amount to be Charged: \$

U.S. Application No.10/590,450; Atty Docket No.1090-127

a. ☐ A check in the amount of \$40.00 to cover the above fees is enclosed.

- b. ☐ Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees.
A duplicate copy of this form is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed.
- d. ☐ **CREDIT CARD PAYMENT FORM ATTACHED.**
- e. ☒ The entire content of International Application No. **PCT/GB2005/000780** and any U.S. and foreign application(s) corresponding thereto, and _____, referred to in this application is/are hereby incorporated by reference in this application.

NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b) must be filed and granted to restore the application to pending status.

CORRESPONDENCE ADDRESS


Direct all correspondence to:

☒ **Customer Number:**

23117

Type Customer Number here

Telephone: (703) 816-4000
LCM:iff


Leonard C. Mitchard
NAME

29,009

November 27, 2006

REGISTRATION NUMBER

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

OLOFSSON et al

Atty. Ref.: 1090-127; Confirmation No.

Appl. No. 10/590,450

TC/A.U. Unassigned

Filed: August 24, 2006

Examiner: Unassigned

For: USE OF NEW LIPOXYGENASE INHIBITORS

* * * * *

November 27, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

IDENTIFICATION OF PRACTITIONERS TO BE RECOGNIZED

Of the Patent Practitioners identified in the concurrently filed Power of Attorney, please recognize the following listed Patent Practitioners as being of record in the above-identified application/patent.

Listing of Practitioners of Record (No more than 10)


Larry S. Nixon	Reg. No. 25,640
Arthur R. Crawford	Reg. No. 25,327
Robert W. Faris	Reg. No. 31,352
Mark E. Nusbaum	Reg. No. 32,348
Michael J. Keenan	Reg. No. 32, 106
Jeffry H. Nelson	Reg. No. 30,481
John R. Lastova	Reg. No. 33,149
H. Warren Burnam, Jr.	Reg. No. 29,366
Michael J. Shea	Reg. No. 34,725
Leonard C. Mitchard	Reg. No. 29,009

OLOFSSON et al
Appl. No. 10/590,450
November 27, 2006

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lff
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

OLOFSSON et al

Atty. Ref.: 1090-127

Serial No. Unassigned

Group: Unassigned

Filed: August 24, 2006

Examiner: Unassigned

For: USE OF NEW LIPOXYGENASE INHIBITORS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**EXCLUSIVE SUBSTITUTE POWER OF ATTORNEY
AND EXCLUSIVE PROSECUTION HEREAFTER BY
ASSIGNEE UNDER 37 C.F.R. §§ 1.36, 3.71 AND 3.73**

Biolipox AB, being the owner of all right, title and interest in the above-identified patent application, hereby revokes all previous powers of attorney in this case, if any, and hereby appoints the attorneys of **Customer Number 23117** individually and collectively its attorneys to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith, and with the resulting patent.

Biolipox AB also authorizes Nixon & Vanderhye to act and rely solely on instructions communicated from the person, attorney, firm or other organization sending instructions to Nixon & Vanderhye on behalf of the owner.

Certificate Under 37 C.F.R. §3.73(b)

Biolipox AB, a corporation having a place of business at P.O. Box 6280, Stockholm, Sweden S-102 34 states that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors to the aforesaid assignee, a copy of the assignment being attached.

The undersigned (whose title is typed below) is empowered to sign this statement on behalf of Biolipox AB.

OCTOBER 17, 2006

Date

By:

Biolipox AB

Name:

Title:

TURBIDAN BJORKE
PRESIDENT & CEO